TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 17311685
Drug: Educational intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Educational intervention using postcards and posters on depression and its treatment
Study: 9543445
Drug: gp160 in
Normalized name: Gp160 Vaccine
DrugBank: VaxSyn (DB17827)
Approvals — FDA: no, EMA: no, PMDA: no
Description: gp160 in alum over a 2‐year period in combination with zidovudine (n = 34)
Study: 9543445
Drug: alum over
Normalized name: alum
Approvals — FDA: no, EMA: no, PMDA: no
Description: alum over a 2‐year period in combination with zidovudine (n = 33)
Study: 3143277
Drug: Urapidil (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Urapidil (60 mg orally thrice a day)
Study: 20528706
Drug: Stepped care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stepped care model (including watchful waiting, guided self-help, brief psychotherapy, longer-term psychotherapy, and antidepressant medication)
Study: 20528706
Drug: Longer-term face-to-face
Normalized name: FACE SHIELD
Approvals — FDA: no, EMA: no, PMDA: no
Description: Longer-term face-to-face psychotherapy and antidepressant medication
Study: 12648863
Drug: Magnesium sulphate
Normalized name: Magnesium sulphate
DrugBank: Magnesium (DB14513)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Magnesium sulphate (4.0 g loading dose over 30 min, followed by 1-2 g/hour continuous infusion for up to 21 days)
Study: 3529153
Drug: Verapamil (calcium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Verapamil (calcium antagonist) at doses of 320-480 mg/day
Study: 17493509
Drug: M. charantia
Approvals — FDA: no, EMA: no, PMDA: no
Description: M. charantia capsules (two capsules three times a day after meals for 3 months)
Study: 17493509
Drug: Placebo (two
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (two capsules three times a day after meals for 3 months)
Study: 17493509
Drug: M. charantia
Approvals — FDA: no, EMA: no, PMDA: no
Description: M. charantia capsules
Study: 21327805
Drug: Midazolam 0.5
Normalized name: midazolam 0.5 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam 0.5 mg/kg
Study: 3081928
Drug: Diazepam 0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diazepam 0.3 mg/kg
Study: 8543748
Drug: 15 mg
Normalized name: papain 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg of furosemide
Study: 8543748
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg of furosemide
Study: 2720135
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg nitrofurantoin tablet
Study: 794000
Drug: Indoprofen 600
Normalized name: Neoprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Indoprofen 600 mg daily for 7 days
Study: 794000
Drug: Ibuprofen 900
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ibuprofen 900 mg daily for 7 days
Study: 31474439
Drug: Pegcetacoplan monthly
Normalized name: Pegcetacoplan
DrugBank: Pegcetacoplan (DB16694)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Pegcetacoplan monthly
Study: 31624047
Drug: CVD treatment
Normalized name: Vibrio cholerae CVD 103-HGR strain live antigen Oral Suspension [Vaxchora]
Approvals — FDA: no, EMA: no, PMDA: no
Description: CVD treatment (cyclophosphamide, bortezomib, and dexamethasone)
Study: 16498057
Drug: Rosiglitazone (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rosiglitazone (4 mg daily for 12 weeks)
Study: 8299662
Drug: CL284,846 (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: CL284,846 (20 mg)
Study: 9888613
Drug: Lorazepam (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lorazepam (2 mg)
Study: 24980392
Drug: DX-2930 (0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: DX-2930 (0.3 mg/kg)
Study: 24980392
Drug: DX-2930 (1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: DX-2930 (1.0 mg/kg)
Study: 24980392
Drug: DX-2930 (3.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: DX-2930 (3.0 mg/kg)
Study: 20525230
Drug: Twice the
Normalized name: THE-630
DrugBank: THE-630 (DB16750)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice the recommended dietary allowance of 14 micronutrients for 6 months
Study: 20525230
Drug: Twice the
Normalized name: THE-630
DrugBank: THE-630 (DB16750)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice the recommended dietary allowance of 14 micronutrients in ART stratum
Study: 20525230
Drug: Twice the
Normalized name: THE-630
DrugBank: THE-630 (DB16750)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice the recommended dietary allowance of 14 micronutrients in non-ART stratum
Study: 1830266
Drug: All doses
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All doses of EE2
Study: 6124671
Drug: 1 g
Normalized name: Molds 1 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g methylprednisolone
Study: 19786940
Drug: Half-dose reteplase
Normalized name: reteplase
DrugBank: Reteplase (DB00015)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Half-dose reteplase (r-PA) plus abciximab
Study: 10087431
Drug: Early introduction
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early introduction of fluindione (20 mg once daily starting on day 1)
Study: 10087431
Drug: Delayed introduction
Normalized name: INTRODUCTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delayed introduction of fluindione (20 mg once daily starting on day 10)
Study: 21537337
Drug: Transdermal nitroglycerine
Normalized name: nitroglycerin Transdermal System
DrugBank: Nitroglycerin (DB00727)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal nitroglycerine treatment (1.25 mg patch for 6 months)
Study: 16894240
Drug: Thiazolidinediones (in
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thiazolidinediones (in vitro treatment of 3T3 F442A adipocytes)
Study: 12953340
Drug: Double-strength grapefruit
Normalized name: GRAPEFRUIT
DrugBank: Grapefruit (DB10534)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Double-strength grapefruit juice (DS GFJ) 240 mL tid for 3 days
Study: 12953340
Drug: Single-strength grapefruit
Normalized name: GRAPEFRUIT
DrugBank: Grapefruit (DB10534)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-strength grapefruit juice (SS GFJ) 240 mL
Study: 1513726
Drug: Nebulized albuterol
Normalized name: Albuterol
DrugBank: Albuterol (DB01001)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebulized albuterol (0.15 mg/kg)
Study: 6475060
Drug: Moderately high-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moderately high-dose methotrexate (MTX) 250 mg/m2 to 750 mg/m2 at 10-day intervals
Study: 6475060
Drug: High-dose methotrexate
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose methotrexate (MTX) 5 to 15 g at 10-day intervals
Study: 6475060
Drug: Ultra-high therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultra-high therapy with a cumulative dose of 205 g MTX
Study: 6475060
Drug: Two cases
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two cases of severe malignant non-Hodgkin's lymphoma treated with MTX (1 patient received 2 X 1 g MTX, the other received a single dose of 5 g MTX)
Study: 30592476
Drug: Intranasal ketamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal ketamine (1.5 mg/kg)
Study: 29287863
Drug: Intranasal fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intranasal fentanyl (1.5 mcg/kg)
Study: 29287863
Drug: Intravenous paracetamol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous paracetamol (10 mg/kg)
Study: 23411886
Drug: Dexamethasone intravitreal
Normalized name: Dexamethasone Intravitreal Implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone intravitreal implant
Study: 24612095
Drug: Bevacizumab injections
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bevacizumab injections
Study: 23019837
Drug: Oral Midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral Midazolam (0.5 mg/kg)
Study: 23019837
Drug: Intravenous Midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous Midazolam (0.06 mg/kg)
Study: 23855176
Drug: Oral Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Placebo
Study: 2506337
Drug: Alcohol (0.694
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alcohol (0.694 g of alcohol per kg b.wt.)
Study: 27798224
Drug: Amphetamine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amphetamine (10 mg)
Study: 6548392
Drug: Commercial oral
Normalized name: iodine
DrugBank: Iodine (DB05382)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Commercial oral elixir of theophylline
Study: 6548392
Drug: Rectal suppository
Normalized name: Rectal Suppository
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rectal suppository of aminophylline
Study: 6548392
Drug: Rectal enema
Normalized name: Fleet Rectal Enema
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rectal enema of theophylline monoethanolamine
Study: 30176671
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg WP-0508ST
Study: 30176671
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg WP-0508ST
Study: 24939916
Drug: Treatment as
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment as usual control (n = 101)
Study: 10350027
Drug: Amisulpride 400
Normalized name: amisulpride 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amisulpride 400 mg
Study: 7548709
Drug: Two-stage sequential
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two-stage sequential design with variance-based weights for treatment effects
Study: 26643240
Drug: Fondaparinux sodium,
Normalized name: Fondaparinux Sodium, 5 mg/0.4 mL subcutaneous solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fondaparinux sodium, 2.5 mg, 1/d for 11 d
Study: 17653532
Drug: Mirtazapine (7.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mirtazapine (7.5 mg)
Study: 16497273
Drug: Mirtazapine (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mirtazapine (15 mg)
Study: 15853576
Drug: Natalizumab (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Natalizumab (300 mg intravenous infusion, administered monthly)
Study: 29171139
Drug: linagliptin 5
Normalized name: linagliptin 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: linagliptin 5 mg
Study: 23507346
Drug: Pelvic fitness
Normalized name: Sus scrofa renal pelvis preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pelvic fitness program (6-week duration, twice a week)
Study: 14609611
Drug: Physiologic testosterone
Normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Physiologic testosterone therapy
Study: 18092150
Drug: Terlipressin (TP)
DrugBank: Terlipressin (DB02638)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terlipressin (TP) administered as intravenous bolus doses of 20 microg/kg every 6 h for a maximum of 96 h
Study: 10683715
Drug: Diclofenac potassium
Normalized name: Diclofenac Potassium
DrugBank: Diclofenac (DB00586)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Diclofenac potassium salt 50 mg in sachet (Voltfast)
Study: 8229120
Drug: IL-3 at
Approvals — FDA: no, EMA: no, PMDA: no
Description: IL-3 at doses > or = 2.5 micrograms/kg
Study: 25236397
Drug: Smaller pouch
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Smaller pouch size group (10-20 ml)
Study: 21669298
Drug: Hydroxychloroquine therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydroxychloroquine therapy for newly diagnosed extensive cGVHD
Study: 12850361
Drug: RSV PFP-2
Normalized name: RSV-IGIV
DrugBank: Respigam (DB17765)
Approvals — FDA: no, EMA: no, PMDA: no
Description: RSV PFP-2 vaccine
Study: 8724922
Drug: 6% glucose/sucrose
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6% glucose/sucrose solution at the rate of 0.6 g.kg‐1 (Body Weight).hr.‐1
Study: 11486115
Drug: Concurrent controls
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent controls (9 patients)
Study: 8651473
Drug: Nedocromil sodium
Normalized name: Nedocromil Sodium
DrugBank: Nedocromil (DB00716)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nedocromil sodium 1% nasal spray QID + astemizole
Study: 8651473
Drug: Placebo nasal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo nasal spray + astemizole
Study: 8651473
Drug: Combined therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined therapy (nedocromil sodium + astemizole)
Study: 1347103
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg lovastatin daily
Study: 1347103
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg lovastatin daily
Study: 6734045
Drug: Nifedipine (18.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine (18.5 +/- 4 mg every 8 hr)
Study: 31903334
Drug: Tranexamic acid
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tranexamic acid (TA) only, 50 mg/kg administered intravenously before surgery
Study: 31903334
Drug: Tranexamic acid
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tranexamic acid combined with vitamin C (TXC), 50 mg/kg TA and 2 g vitamin C with 100 mL 0.9% saline administered before surgery and daily infusions post-operation
Study: 24086333
Drug: Daily oral
Normalized name: GEMTESA 75 MG Once-Daily Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily oral Tenofovir/Emtricitabine (TDF/FTC‐Truvada)
Study: 24086333
Drug: Intermittent oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent oral Tenofovir/Emtricitabine (TDF/FTC)
Study: 24086333
Drug: Post‐coital dosing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Post‐coital dosing of Tenofovir/Emtricitabine (TDF/FTC)
Study: 17110217
Drug: Dutasteride 2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dutasteride 2.5 mg
Study: 3123091
Drug: Intravenous rt-PA
Normalized name: rt-PA
DrugBank: Alteplase (DB00009)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous rt-PA (50 mg over 2 hr)
Study: 3123091
Drug: Intrapulmonary rt-PA
Normalized name: rt-PA
DrugBank: Alteplase (DB00009)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intrapulmonary rt-PA (50 mg over 2 hr)
Study: 3123091
Drug: Intrapulmonary rt-PA
Normalized name: rt-PA
DrugBank: Alteplase (DB00009)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intrapulmonary rt-PA (100 mg over 5 hr)
Study: 3123091
Drug: Intravenous rt-PA
Normalized name: rt-PA
DrugBank: Alteplase (DB00009)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous rt-PA (100 mg over 5 hr)
Study: 3123091
Drug: Both groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both groups (Intravenous and Intrapulmonary rt-PA)
Study: 29899061
Drug: Nicotine patch
Normalized name: Nicotine Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicotine patch (21 mg) for four weeks before quitting
Study: 29899061
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (standard smoking cessation pharmacotherapy and behavioral support)
Study: 27583380
Drug: Inhaled nitric
Normalized name: nitric oxide Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled nitric oxide alone
Study: 19236622
Drug: Blood glucose
Normalized name: Blood Glucose Book
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blood glucose <= 8.0 mmol/l
Study: 16551889
Drug: Antithrombin (3000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antithrombin (3000 U infused over 30 min before heparin administration and 24 h later)
Study: 16551889
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no antithrombin infusion)
Study: 9376645
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg melatonin at 20:00 h on Days 1 to 15 (Melatonin 1st)
Study: 7902484
Drug: Pamidronate therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pamidronate therapy (180 or 360 mg during 6 or 9 weeks)
Study: 7902484
Drug: Pamidronate therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pamidronate therapy (45 mg every 3 months for 1 year)
Study: 28386783
Drug: Dexamethasone, total
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone, total dose of 30 mg perioperatively
Study: 23596788
Drug: Modified Taohe
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modified Taohe Chengqi Granule (MTCG) combined with intravenous dripping of mannitol
Study: 23596788
Drug: Intravenous dripping
Normalized name: DRIP COLLECTOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous dripping of mannitol alone
Study: 17192498
Drug: Fasudil HCl
Normalized name: Chlorpromazine Hydrochloride
DrugBank: Fasudil (DB08162)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Fasudil HCl administered as solution to the ascending colon
Study: 17192498
Drug: Fasudil HCl
Normalized name: Chlorpromazine Hydrochloride
DrugBank: Fasudil (DB08162)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Fasudil HCl administered as powder to the ascending colon
Study: 17192498
Drug: Fasudil HCl
Normalized name: Chlorpromazine Hydrochloride
DrugBank: Fasudil (DB08162)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Fasudil HCl administered orally as an immediate-release tablet
Study: 2929903
Drug: Lignocaine 1
Normalized name: lidocaine hydrochloride Injectable Solution [Sure-Amp Lignocaine hydrochloride]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lignocaine 1 mg/kg
Study: 25954849
Drug: Individualized heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Individualized heparin management (IHM)
Study: 23962470
Drug: Intrathecal fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intrathecal fentanyl 10 μg
Study: 21372608
Drug: Metformin +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin + lifestyle (ML)
Study: 29546579
Drug: Metformin (in
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin (in vitro)
Study: 17135672
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of LPS + BGL
Study: 8827547
Drug: Artificial surfactant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Artificial surfactant therapy for hyaline membrane disease (HMD)
Study: 6486080
Drug: Zinc supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zinc supplementation (25 mg, two daily doses)
Study: 24777150
Drug: Esomeprazole IV
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esomeprazole IV bolus at a dose of 80 mg plus infusion at 8 mg/h for 72 h and oral placebo every 12 h (IVP group)
Study: 24777150
Drug: High-dose oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose oral esomeprazole at a dose of 40 mg every 12 h (ORP group)
Study: 11300382
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose L-arginine (n=10)
Study: 11300382
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose L-arginine (n=10)
Study: 3145948
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg of flurazepam taken the night before surgery
Study: 28679180
Drug: Placebo (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (1 suppository/day for 1 month)
Study: 18186996
Drug: Bulb syringe
Normalized name: Bulb Syringe
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bulb syringe self-treatment
Study: 14693310
Drug: Intramuscular interferon
Normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular interferon beta‐1a (IFNβ‐1a) 30 μg IM once weekly
Study: 1749978
Drug: Intravenous narcotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous narcotics
Study: 6195981
Drug: Hydroxyethyl starch
Normalized name: Hydroxyethyl starch
DrugBank: Hydroxyethyl Starch (DB09106)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydroxyethyl starch (HES) 1,000 ml
Study: 6195981
Drug: 25% albumin
Normalized name: Flexbumin 25% Albumin (Human) Solution for Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25% albumin 200 ml
Study: 18257182
Drug: Acup‐moxibustion treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acup‐moxibustion treatment
Study: 15766996
Drug: Rasagiline (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rasagiline (1 mg once daily)
Study: 15766996
Drug: Entacapone (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Entacapone (200 mg with every levodopa dose)
Study: 2040104
Drug: Piroxicam 0.5%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Piroxicam 0.5% gel (5 mg q.i.d.)
Study: 7325344
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of peridural anaesthesia and neuroleptanalgesia (PDA/NLA)
Study: 19099547
Drug: 0.5-2% chitin-glucan
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5-2% chitin-glucan applied twice daily
Study: 19099547
Drug: 1.5% chitin-glucan
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5% chitin-glucan formulation applied twice daily
Study: 11967499
Drug: Raloxifene 150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Raloxifene 150 mg
Study: 1723455
Drug: Nitrendipine 10
Normalized name: nitrendipine 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitrendipine 10 mg once daily
Study: 7472173
Drug: Phenobarbital (Luminal)
Normalized name: Phenobarbital
DrugBank: Phenobarbital (DB01174)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phenobarbital (Luminal) 15 mg/kg intramuscularly
Study: 7472173
Drug: Phenobarbital (Luminal)
Normalized name: Phenobarbital
DrugBank: Phenobarbital (DB01174)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phenobarbital (Luminal) 5 mg/kg orally or intramuscularly
Study: 28818050
Drug: Probiotic administration
Normalized name: Rezyst Probiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotic administration
Study: 23380438
Drug: PRM‐151 (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: PRM‐151 (10 mg/kg)
Study: 18832751
Drug: rHDL (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: rHDL (80 mg/kg given over 4 hours)
Study: 11304763
Drug: Topotecan (1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topotecan (1.5 mg/m²/d for 5 days, every 3 weeks)
Study: 23566071
Drug: 5% sterile
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5% sterile topical royal jelly
Study: 14595527
Drug: Withdrawal of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Withdrawal of SSRI drugs (intervention group, n=35)
Study: 14595527
Drug: No change
Approvals — FDA: no, EMA: no, PMDA: no
Description: No change in treatment (control group, n=35)
Study: 11110743
Drug: Multifaceted intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Multifaceted intervention promoting early switch from intravenous to oral acetaminophen